DK1035115T3 - 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister - Google Patents

4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister

Info

Publication number
DK1035115T3
DK1035115T3 DK00102260T DK00102260T DK1035115T3 DK 1035115 T3 DK1035115 T3 DK 1035115T3 DK 00102260 T DK00102260 T DK 00102260T DK 00102260 T DK00102260 T DK 00102260T DK 1035115 T3 DK1035115 T3 DK 1035115T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
phenylpyridine derivatives
phenylpyridine
derivatives
antagonists
Prior art date
Application number
DK00102260T
Other languages
Danish (da)
English (en)
Inventor
Michael Boes
Quirico Branca
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1035115T3 publication Critical patent/DK1035115T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK00102260T 1999-02-24 2000-02-15 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister DK1035115T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (1)

Publication Number Publication Date
DK1035115T3 true DK1035115T3 (da) 2005-01-24

Family

ID=26152908

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00102260T DK1035115T3 (da) 1999-02-24 2000-02-15 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
DK03026298.4T DK1394150T3 (da) 1999-02-24 2000-02-15 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03026298.4T DK1394150T3 (da) 1999-02-24 2000-02-15 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister

Country Status (54)

Country Link
US (2) US6297375B1 (index.php)
EP (2) EP1394150B1 (index.php)
JP (1) JP3399900B2 (index.php)
KR (1) KR100384904B1 (index.php)
CN (1) CN1142144C (index.php)
AR (2) AR029614A1 (index.php)
AT (2) ATE277905T1 (index.php)
AU (1) AU767048B2 (index.php)
BE (1) BE2015C057I2 (index.php)
BG (1) BG64554B1 (index.php)
BR (1) BRPI0000908B8 (index.php)
CA (1) CA2299139C (index.php)
CY (3) CY1111317T1 (index.php)
CZ (1) CZ300596B6 (index.php)
DE (3) DE60045564D1 (index.php)
DK (2) DK1035115T3 (index.php)
EA (1) EA003673B1 (index.php)
EG (1) EG23817A (index.php)
ES (3) ES2226622T3 (index.php)
FR (2) FR2790473B1 (index.php)
GB (1) GB2347422A (index.php)
GE (1) GEP20022676B (index.php)
GT (1) GT200000017A (index.php)
HR (2) HRP20000097B1 (index.php)
HU (1) HU227629B1 (index.php)
IL (1) IL134654A (index.php)
IS (1) IS2116B (index.php)
IT (1) IT1320763B1 (index.php)
JO (1) JO2294B1 (index.php)
LT (1) LTC1035115I2 (index.php)
LU (1) LU92745I2 (index.php)
MA (1) MA26722A1 (index.php)
ME (1) ME00593B (index.php)
MY (2) MY123648A (index.php)
NL (1) NL300758I1 (index.php)
NO (1) NO315554B1 (index.php)
NZ (1) NZ502948A (index.php)
OA (1) OA11680A (index.php)
PA (1) PA8491101A1 (index.php)
PE (1) PE20001467A1 (index.php)
PL (1) PL217311B1 (index.php)
PT (2) PT1035115E (index.php)
RS (3) RS20080562A (index.php)
SE (1) SE1035115T5 (index.php)
SG (1) SG91856A1 (index.php)
SI (1) SI1035115T1 (index.php)
SK (2) SK287911B6 (index.php)
SV (1) SV2002000024A (index.php)
TN (1) TNSN00032A1 (index.php)
TR (1) TR200000520A3 (index.php)
TW (1) TWI288746B (index.php)
UA (1) UA71547C2 (index.php)
UY (1) UY32314A (index.php)
ZA (1) ZA200000894B (index.php)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058640A2 (en) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
PL350427A1 (en) * 1999-02-24 2002-12-16 Hoffmann La Roche Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
TR200302077T4 (tr) * 1999-11-29 2004-01-21 F. Hoffmann-La Roche Ag 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 セントラル硝子株式会社 光学活性α−メチル−ビス−３、５−（トリフルオロメチル）ベンジルアミンの製造方法
BRPI0112475B8 (pt) * 2000-07-14 2021-05-25 Hoffmann La Roche n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
WO2002047663A1 (en) 2000-12-14 2002-06-20 F. Hoffman-La Roche Ag Self emulsifying lipid matrix (selm)
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
ATE366248T1 (de) * 2001-03-27 2007-07-15 Eisai R&D Man Co Ltd N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
CN100398106C (zh) * 2001-04-23 2008-07-02 弗·哈夫曼-拉罗切有限公司 Nk-1受体拮抗剂对抗良性前列腺增生的用途
EP2266558B1 (en) * 2001-06-07 2017-04-19 Analgesic Neuropharmaceuticals, LLC Treatment of neuropathic pain with the N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
RU2302233C2 (ru) * 2001-09-10 2007-07-10 Ф.Хоффманн-Ля Рош Аг Масляные тиксотропные композиции
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
JP2006508061A (ja) 2002-09-20 2006-03-09 ファイザー・プロダクツ・インク エストロゲン受容体に対するアミドおよびスルホンアミドリガンド
US7244748B2 (en) * 2002-12-06 2007-07-17 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
KR100700421B1 (ko) * 2003-01-31 2007-03-28 에프. 호프만-라 로슈 아게 2-(3,5-비스-트라이플루오로메틸-페닐)-Ｎ-[6-(1,1-다이옥소-1λ6-티오모폴린-4-일)-4-(4-플루오로-2-메틸-페닐)-피리딘-3-일]-Ｎ-메틸-아이소부티르아미드의 새로운 결정변형체
AU2004253267B2 (en) * 2003-07-03 2008-12-04 F. Hoffmann-La Roche Ag Dual NK1/NK3 antagonists for treating schizophrenia
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
EP1776342B1 (en) * 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
WO2006014168A1 (en) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20060135636A1 (en) * 2004-11-15 2006-06-22 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
WO2006089658A2 (en) 2005-02-22 2006-08-31 F. Hoffmann-La Roche Ag Nk1 antagonists
JP2008531592A (ja) * 2005-02-24 2008-08-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カリウムイオンチャンネル開口薬としての新規なピリジン誘導体
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
DK1863767T3 (da) * 2005-03-23 2009-05-04 Hoffmann La Roche Metabolitter til NK-I-antagonister til emesis
WO2007130075A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
MX2008002019A (es) * 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
KR101292348B1 (ko) 2005-09-09 2013-09-09 네르 쎄라퓨틱스 리미티드 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도
NZ566419A (en) * 2005-09-23 2010-03-26 Hoffmann La Roche Novel dosage formulation
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
HUE036165T2 (hu) 2006-04-07 2018-06-28 Vertex Pharma ATP-kötõ kazetta transzportereinek modulátorai
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
NZ599684A (en) 2007-12-07 2013-08-30 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
KR20160040745A (ko) 2007-12-07 2016-04-14 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
US20100317663A1 (en) * 2008-02-19 2010-12-16 Jerry Leroy Adams Anilinopyridines as inhibitors of fak
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
US8796269B2 (en) * 2009-08-27 2014-08-05 Nerre Therapeutics Limited Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2722044B1 (en) 2009-11-18 2017-01-04 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP2013523836A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の固体形態
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
JP2013525371A (ja) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) * 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2736329A4 (en) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
EP2747560A4 (en) * 2011-07-29 2015-02-25 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
CN105412110B (zh) 2011-10-18 2018-05-25 赫尔森保健股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
KR101985044B1 (ko) 2011-11-08 2019-05-31 버텍스 파마슈티칼스 인코포레이티드 Atp-결합 카세트 수송체의 조절제
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
UA114619C2 (uk) 2012-01-25 2017-07-10 Вертекс Фармасьютікалз Інкорпорейтед СКЛАД 3-(6-(1-(2,2-ДИФТОРОБЕНЗО[d][1,3]ДІОКСОЛ-5-ІЛ)ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
KR20160078997A (ko) 2013-11-08 2016-07-05 깃세이 야쿠힌 고교 가부시키가이샤 카복시메틸피페리딘 유도체
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
ES2675858T3 (es) 2014-04-15 2018-07-13 Vertex Pharmaceuticals Incorporated Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
EP3140007A1 (en) * 2014-05-05 2017-03-15 Apicore US LLC Methods of making netupitant and intermediates thereof
TWI649307B (zh) * 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
RS62259B1 (sr) 2014-11-18 2021-09-30 Vertex Pharma Proces izvođenja ispitivanja visoke propusnosti tečne hromatografije visokih performansi
KR20170122777A (ko) 2015-03-04 2017-11-06 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017099049A1 (ja) * 2015-12-07 2017-06-15 キッセイ薬品工業株式会社 Ｎｋ１受容体拮抗剤
TWI773657B (zh) * 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
EP3393519A1 (en) 2015-12-22 2018-10-31 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
CN109384712B (zh) * 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
BR112020015484A2 (pt) * 2018-09-28 2021-04-27 Vanda Pharmaceuticals Inc. métodos para tratamento de um sujeito prestes a se envolver em uma atividade que implica em movimento indutor de enjoo e de um sujeito com enjoo de movimento ou pelo menos um sintoma de enjoo de movimento, composto, e, composição farmacêutica
JP7587215B2 (ja) * 2018-12-24 2024-11-20 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 化合物の製造、その新しい塩形態および治療的使用
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
CN114466683A (zh) * 2019-08-23 2022-05-10 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 治疗方法及其用途
MX2022011545A (es) 2020-04-03 2022-11-09 Nerre Therapeutics Ltd Un antagonista de receptor de nk-1 para tratar una enfermedad que se selecciona de sepsis, choque septico, síndrome de dificultad respiratoria aguda (ards) 0 síndrome de disfunción orgánica múltiple (mcds).
CN115697332A (zh) 2020-06-02 2023-02-03 尼尔医疗有限公司 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
KR20250125376A (ko) 2022-12-12 2025-08-21 알프레드 이. 티펜바흐어 게엠베하 운트 ＆ 코. 카게 네투피탄트 및 팔로노세트론을 포함하는 고정 용량 복합제

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에르 위브 신규한 이소부티라미드류의 제조방법
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에르 위브 이소부티라미드 유도체의 신규한 제조방법
EP0089765A3 (en) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994003429A1 (en) 1992-07-31 1994-02-17 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) * 1993-12-29 2005-03-22 Raymond Baker Substituted morpholine derivatives and their use as therapeutic agents
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
PT764163E (pt) 1994-06-06 2002-03-28 Warner Lambert Co Antagonistas do receptor de taquiquinina (nk1)
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
EP0891332B1 (en) 1996-03-29 2004-03-17 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
PL350427A1 (en) * 1999-02-24 2002-12-16 Hoffmann La Roche Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
TR200302077T4 (tr) * 1999-11-29 2004-01-21 F. Hoffmann-La Roche Ag 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit

Also Published As

Publication number Publication date
ITMI20000328A0 (it) 2000-02-23
EG23817A (en) 2007-09-19
HRP20000097B1 (en) 2008-12-31
CN1270959A (zh) 2000-10-25
KR20000062599A (ko) 2000-10-25
AU767048B2 (en) 2003-10-30
FR15C0049I2 (fr) 2016-02-12
EP1394150B1 (en) 2011-01-19
NL300758I2 (index.php) 2015-12-22
ZA200000894B (en) 2000-08-24
LTC1035115I2 (lt) 2017-04-10
HK1031223A1 (en) 2001-06-08
BE2015C057I2 (index.php) 2019-03-06
FR15C0049I1 (fr) 2015-08-28
CZ300596B6 (cs) 2009-06-24
IS5381A (is) 2000-08-25
HUP0000748A3 (en) 2003-12-29
LU92745I2 (fr) 2015-08-17
PE20001467A1 (es) 2000-12-20
ITMI20000328A1 (it) 2001-08-23
BR0000908A (pt) 2000-09-12
SE1035115T3 (sv) 2005-01-18
SK287911B6 (sk) 2012-03-02
CY2015041I1 (el) 2016-06-22
UA71547C2 (uk) 2004-12-15
UY32314A (es) 2010-02-26
DE60014216D1 (de) 2004-11-04
IS2116B (is) 2006-06-15
SV2002000024A (es) 2002-01-23
IL134654A0 (en) 2001-04-30
AU1946800A (en) 2000-08-31
TWI288746B (en) 2007-10-21
MY147451A (en) 2012-12-14
TR200000520A2 (tr) 2001-06-21
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (sr) 2015-08-31
HUP0000748A2 (en) 2001-03-28
NO315554B1 (no) 2003-09-22
TNSN00032A1 (fr) 2005-11-10
GT200000017A (es) 2001-08-15
JP2000247957A (ja) 2000-09-12
CZ2000609A3 (cs) 2001-01-17
CY1111317T1 (el) 2015-08-05
CA2299139A1 (en) 2000-08-24
OA11680A (fr) 2005-01-12
GEP20022676B (en) 2002-04-25
SK287912B6 (sk) 2012-03-02
MY123648A (en) 2006-05-31
DK1394150T3 (da) 2011-03-21
ATE277905T1 (de) 2004-10-15
SG91856A1 (en) 2002-10-15
SE1035115T5 (sv) 2015-08-04
YU9500A (sh) 2002-11-15
IT1320763B1 (it) 2003-12-10
EA200000155A2 (ru) 2000-08-28
PL217311B1 (pl) 2014-07-31
RS20080562A (sr) 2009-09-08
DE60045564D1 (de) 2011-03-03
DE60014216T2 (de) 2006-03-02
ES2359235T3 (es) 2011-05-19
IL134654A (en) 2011-03-31
EP1035115B1 (en) 2004-09-29
MA26722A1 (fr) 2004-12-20
US20020091265A1 (en) 2002-07-11
DE10008042A1 (de) 2000-08-31
GB0003908D0 (en) 2000-04-05
HRP20080306A2 (en) 2008-11-30
US6297375B1 (en) 2001-10-02
JP3399900B2 (ja) 2003-04-21
HRP20000097A2 (en) 2001-10-31
ES2171109B2 (es) 2003-09-16
HU0000748D0 (en) 2000-04-28
JO2294B1 (en) 2005-09-12
NO20000885L (no) 2000-08-25
PT1035115E (pt) 2005-01-31
EP1394150A1 (en) 2004-03-03
CA2299139C (en) 2011-03-29
SI1035115T1 (en) 2005-02-28
BRPI0000908B8 (pt) 2021-05-25
RS50194B (sr) 2009-05-06
NO20000885D0 (no) 2000-02-23
EA003673B1 (ru) 2003-08-28
AR062949A2 (es) 2008-12-17
MEP5709A (en) 2011-12-20
PL338598A1 (en) 2000-08-28
KR100384904B1 (ko) 2003-05-22
ES2226622T3 (es) 2005-04-01
BG104187A (en) 2000-11-30
SK2352000A3 (en) 2000-09-12
CN1142144C (zh) 2004-03-17
NZ502948A (en) 2001-09-28
CY2015041I2 (el) 2016-06-22
US6479483B2 (en) 2002-11-12
AR029614A1 (es) 2003-07-10
HRP20080306B1 (hr) 2015-01-30
NL300758I1 (index.php) 2015-12-22
PA8491101A1 (es) 2001-04-30
BG64554B1 (bg) 2005-07-29
GB2347422A (en) 2000-09-06
PT1394150E (pt) 2011-02-17
HU227629B1 (en) 2011-10-28
FR2790473A1 (fr) 2000-09-08
FR2790473B1 (fr) 2004-04-02
CY2015042I1 (el) 2016-06-22
ATE496032T1 (de) 2011-02-15
ME00593B (me) 2015-08-31
TR200000520A3 (tr) 2001-06-21
EP1035115A1 (en) 2000-09-13
BR0000908B1 (pt) 2013-09-24
ES2171109A1 (es) 2002-08-16
EA200000155A3 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
DK1035115T3 (da) 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
DK1157005T3 (da) 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
NO20013809L (no) Indolderivater og anvendelse derav som MCP-1 antagonister
NO985225L (no) Indolderivater nyttige som endotelinreseptorantagonister
NO20021719L (no) 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
NO20021689D0 (no) 5-rings heterosykliske derivater, fremstilling derav og anvendelse som medikamenter
NO20043064L (no) 1-alkyl-1-azoniabisyklo [2.2.2] oktankarbamatderivater og anvendelse av disse som muskarine reseptorantagonister
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DE60026169D1 (de) Selektive neurokinin-antagonisten
DK1345937T3 (da) Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20031952L (no) 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
NO995482L (no) Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister
NO20015897D0 (no) Indolylpiperidinderivater som antihistaminiske og antiallergiske midler
NO20025762L (no) Bicykliske cykloheksylaminer og anvendelse derav som NMDA- reseptorantagonister
DK1335906T3 (da) Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
IS6420A (is) Setnar Fenýl-píperazín afleiður, framleiðsla þeirra og notkun
NO971136D0 (no) Aminoalkyl- og acylaminoaklyleter, fremgangsmåte for fremstilling derav og anvendelse som bradykinin-reseptor antagonister
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
NO992976L (no) Heterocykliske karboksylsyre-derivater, fremstilling og anvendelse derav som endothelinreseptor-antagonister
NO20022455D0 (no) Sulfonyloksazolaminer og deres anvendelse som 5-HT6- reseptorligander
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate
HUP0201540A3 (en) Serotomin and 5ht1a receptor antagonist phenoxypropylamine derivatives and use thereof